Tango Therapeutics, Inc. $TNGX Shares Purchased by Profund Advisors LLC

Posted by George Bondi on May 23rd, 2026

Profund Advisors LLC boosted its position in Tango Therapeutics, Inc. (NASDAQ:TNGX – Free Report) by 167.7% during the 4th quarter, Holdings Channel reports. The fund owned 83,759 shares of the company’s stock after acquiring an additional 52,471 shares during the quarter. Profund Advisors LLC’s holdings in Tango Therapeutics were worth $742,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Tudor Investment Corp ET AL acquired a new stake in Tango Therapeutics in the third quarter valued at approximately $450,000. Farallon Capital Management LLC increased its stake in Tango Therapeutics by 17.5% in the third quarter. Farallon Capital Management LLC now owns 10,757,000 shares of the company’s stock valued at $90,359,000 after purchasing an additional 1,600,000 shares during the last quarter. Mass General Brigham Inc purchased a new position in Tango Therapeutics in the fourth quarter valued at approximately $3,138,000. Rafferty Asset Management LLC purchased a new position in Tango Therapeutics in the third quarter valued at approximately $1,221,000. Finally, Avoro Capital Advisors LLC purchased a new position in Tango Therapeutics in the third quarter valued at approximately $4,578,000. Institutional investors and hedge funds own 78.99% of the company’s stock.

Tango Therapeutics Stock Down 6.4%

Shares of Tango Therapeutics stock opened at $20.24 on Friday. The firm has a market capitalization of $2.93 billion, a P/E ratio of -24.39 and a beta of 1.22. The firm’s 50 day moving average is $21.98 and its two-hundred day moving average is $14.69. Tango Therapeutics, Inc. has a 52 week low of $1.79 and a 52 week high of $28.41.

Tango Therapeutics (NASDAQ:TNGX – Get Free Report) last announced its earnings results on Wednesday, May 13th. The company reported ($0.32) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.32). Tango Therapeutics had a negative net margin of 151.15% and a negative return on equity of 41.54%. As a group, research analysts expect that Tango Therapeutics, Inc. will post -1.34 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have commented on TNGX. Jefferies Financial Group lowered shares of Tango Therapeutics from a “buy” rating to a “hold” rating and increased their price target for the company from $18.00 to $27.00 in a research note on Thursday, May 14th. Mizuho increased their price target on shares of Tango Therapeutics from $20.00 to $30.00 and gave the company an “outperform” rating in a research note on Friday, May 15th. B. Riley Financial reiterated a “buy” rating on shares of Tango Therapeutics in a research note on Friday, March 27th. Stifel Nicolaus increased their price target on shares of Tango Therapeutics from $24.00 to $40.00 and gave the company a “buy” rating in a research note on Monday, April 27th. Finally, Leerink Partners increased their price target on shares of Tango Therapeutics from $28.00 to $55.00 and gave the company an “outperform” rating in a research note on Thursday, May 14th. Ten investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $32.27.

Check Out Our Latest Stock Analysis on Tango Therapeutics

Insider Activity

In other news, insider Adam Crystal sold 54,345 shares of the firm’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $12.77, for a total transaction of $693,985.65. Following the transaction, the insider directly owned 132,873 shares in the company, valued at approximately $1,696,788.21. This trade represents a 29.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have sold 179,056 shares of company stock worth $3,346,181 in the last 90 days. Company insiders own 6.50% of the company’s stock.

Tango Therapeutics Profile

(Free Report)

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.